Form 4: Intra-Cellular Therapies CFO Lawrence Hineline Reports Stock Sales and Option Exercises

Lawrence J. Hineline, CFO of Intra-Cellular Therapies, reported the sale of common stock and the exercise of stock options and restricted stock units between March 7 and March 11, 2024.

Summary

• Lawrence J. Hineline, the SVP of Finance and CFO of Intra-Cellular Therapies, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 7, 2024, Hineline sold 6,514 shares of common stock at $66.26 and 6,618 shares at $66.93.
• On March 10, 2024, Hineline exercised options for 4,539 shares at $56.73 and converted 5,582 restricted stock units into common stock.
• Between March 11, 2024, Hineline sold 4,453 shares at $65.28, 1,100 shares at $66.54, and 29 shares at $67.32.
• Additional sales occurred on March 11, 2024, with 4,475 shares sold at $66.47 and 64 shares at $67.12.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2023.
• A majority of the proceeds from these sales will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions by a company executive. It doesn't inherently indicate positive or negative sentiment, as the sales are conducted under a pre-arranged trading plan.

Management Comments

• A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Monitoring insider transactions is a common practice in the financial industry.
• Similar filings are made by executives at companies like Eli Lilly, Pfizer, and Johnson & Johnson, providing a benchmark for understanding insider activity in the pharmaceutical sector.
• The use of 10b5-1 trading plans is a standard practice to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sales by the CFO could be perceived neutrally or slightly negatively by shareholders, depending on their interpretation of the reasons behind the sales.
• The company is not directly impacted, as these are personal transactions of an executive.

Key Dates